These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 16621870

  • 1. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
    Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L.
    Eur Heart J; 2006 May; 27(10):1166-73. PubMed ID: 16621870
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
    Braun OO, Johnell M, Varenhorst C, James S, Brandt JT, Jakubowski JA, Winters KJ, Wallentin L, Erlinge D, Siegbahn A.
    Thromb Haemost; 2008 Oct; 100(4):626-33. PubMed ID: 18841285
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
    Payne CD, Li YG, Brandt JT, Jakubowski JA, Small DS, Farid NA, Salazar DE, Winters KJ.
    Platelets; 2008 Jun; 19(4):275-81. PubMed ID: 18569863
    [Abstract] [Full Text] [Related]

  • 6. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E, PRINCIPLE-TIMI 44 Investigators.
    Circulation; 2007 Dec 18; 116(25):2923-32. PubMed ID: 18056526
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
    Li YG, Ni L, Brandt JT, Small DS, Payne CD, Ernest CS, Rohatagi S, Farid NA, Jakubowski JA, Winters KJ.
    Platelets; 2009 Aug 18; 20(5):316-27. PubMed ID: 19637095
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
    Darlington A, Tello-Montoliu A, Rollini F, Ueno M, Ferreiro JL, Patel R, Desai B, Guzman LA, Bass TA, Angiolillo DJ.
    Thromb Haemost; 2014 Feb 18; 111(2):258-65. PubMed ID: 24154863
    [Abstract] [Full Text] [Related]

  • 10. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
    Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ.
    Am Heart J; 2007 Jan 18; 153(1):66.e9-16. PubMed ID: 17174640
    [Abstract] [Full Text] [Related]

  • 11. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
    Price MJ, Walder JS, Baker BA, Heiselman DE, Jakubowski JA, Logan DK, Winters KJ, Li W, Angiolillo DJ.
    J Am Coll Cardiol; 2012 Jun 19; 59(25):2338-43. PubMed ID: 22698488
    [Abstract] [Full Text] [Related]

  • 12. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
    Payne CD, Li YG, Small DS, Ernest CS, Farid NA, Jakubowski JA, Brandt JT, Salazar DE, Winters KJ.
    J Cardiovasc Pharmacol; 2007 Nov 19; 50(5):555-62. PubMed ID: 18030066
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
    Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ.
    Thromb Haemost; 2008 Feb 19; 99(2):409-15. PubMed ID: 18278193
    [Abstract] [Full Text] [Related]

  • 15. The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.
    Zhu B, Effron MB, Kulkarni MP, Li YG, Jakubowski JA, Miller DL, Baker BA, Luo J, Small DS, Winters KJ.
    J Cardiovasc Pharmacol; 2011 Mar 19; 57(3):317-24. PubMed ID: 21266916
    [Abstract] [Full Text] [Related]

  • 16. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
    Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, Brandt JT, Sugidachi A, Siegbahn A, Wallentin L.
    J Am Coll Cardiol; 2008 Dec 09; 52(24):1968-77. PubMed ID: 19055987
    [Abstract] [Full Text] [Related]

  • 17. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
    Small DS, Farid NA, Li YG, Ernest CS, Payne CD, Salazar DE, Winters KJ.
    Curr Med Res Opin; 2008 Aug 09; 24(8):2251-7. PubMed ID: 18786302
    [Abstract] [Full Text] [Related]

  • 18. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.
    Weerakkody GJ, Jakubowski JA, Brandt JT, Farid NA, Payne CD, Zhu J, Warner MR, Naganuma H, Winters KJ.
    Am J Cardiol; 2007 Jul 15; 100(2):331-6. PubMed ID: 17631093
    [Abstract] [Full Text] [Related]

  • 19. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.
    Weerakkody GJ, Jakubowski JA, Brandt JT, Payne CD, Naganuma H, Winters KJ.
    J Cardiovasc Pharmacol Ther; 2007 Sep 15; 12(3):205-12. PubMed ID: 17875947
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
    Michelson AD, Frelinger AL, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD, TRITON-TIMI 38 Investigators.
    Eur Heart J; 2009 Jul 15; 30(14):1753-63. PubMed ID: 19435740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.